**Glenmark Pharma to Launch Ropivacaine Hydrochloride Injection in the U.S. Market**

*Mumbai/New Jersey, October 23, 2025:* Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., announced the upcoming launch of **Ropivacaine Hydrochloride Injection USP** in the U.S. market. The injection will be available in three single-dose vial strengths — **40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL)** — and is set to begin distribution in **November 2025**. The product is **bioequivalent and therapeutically equivalent** to **Naropin® Injection**, marketed by Fresenius Kabi USA, LLC, and approved under NDA 020533. According to **IQVIA sales data** for the 12-month period ending August 2025, the Naropin® Injection market achieved **annual sales of approximately $20.9 million**. Commenting on the launch, **Marc Kikuchi**, President and Business Head, North America, said, “This launch marks another important addition to Glenmark’s expanding injectable portfolio and reinforces our commitment to offering high-quality and affordable alternatives for patients in need.” Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company with a strong presence in **branded, generics, and OTC** segments across over **80 countries**. The company operates **11 world-class manufacturing facilities** and focuses on therapeutic areas such as **respiratory, dermatology, and oncology**. Glenmark has been recognized among the **Top 100 global biopharmaceutical companies** and **Top 50 generics firms** by industry publications. The launch underscores Glenmark’s continued efforts to strengthen its U.S. injectables business and deliver cost-effective treatment options in key therapeutic categories. *Disclaimer: This article is for informational purposes only and not investment advice.*